FDMT — 4D MOLECULAR THERAPEUTICS IN

Ownership history in Rangeley Capital, LLC  ·  3 quarters on record

This page tracks every 13F SEC filing in which Rangeley Capital, LLC reported a position in 4D MOLECULAR THERAPEUTICS IN (FDMT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.32% (2025 Q3)
Avg. % of fund
0.21%
First filed
2025 Q2
Last filed
2025 Q4
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 38,665 -4,000 -9.4% 0.24% $290K $7.50
2025 Q3 ADDED 42,665 +29,665 +228.2% 0.32% $371K $8.69
2025 Q2 INITIATED 13,000 — — 0.06% $48K $3.71
% of Fund (quarterly)    FDMT price (monthly, adj. close)

Other funds also holding FDMT

As of 2025 Q4 — sorted by position size

Novo Holdings A/S 3Y 7Y 2.13% BVF INC/IL 3Y 7Y 1.17% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 0.43% Parkman Healthcare Partners LLC 3Y 0.36% Privium Fund Management B.V. 3Y 0.29% ARMISTICE CAPITAL, LLC 3Y 7Y 0.17% Evergreen Quality Fund GP, Ltd. 0.14% Burkehill Global Management, LP 0.14% SILVERARC CAPITAL MANAGEMENT, LLC 3Y 0.1% ArrowMark Colorado Holdings LLC 3Y 7Y 0.08%
← Back to Rangeley Capital, LLC Holdings